Lymphocytes, especially CD4+ T cells, are essential for clearance of the yeast-like organism Cryptococcus neoformans from the infected host. The mechanism(s) by which the lymphocytes facilitate elimination of cryptococci has not been elucidated. It is generally thought, however, that lymphocytes reactive with C. neoformans indirectly function by production of lymphokines to enhance clearance of the organism by natural effector cells such as macrophages. In the present study, we assessed the ability of freshly isolated human lymphocytes to interact directly with C. neoformans and to limit the growth of the organism in vitro. We found that large granular lymphocytes (LGL) as well as T cells bound to cryptococcal cells when the lymphocytes were mixed with the cryptococcal cells at a 2:1 ratio. The physical binding interactions of the two lymphocyte populations were different.
Introduction
Cryptococcosis, a disease caused by the ubiquitous yeast-like organism Cryptococcus neoformans, is rapidly climbing to the top of the list of infectious diseases to which AIDS patients succumb (1-3). The increased incidence of cryptococcosis in individuals with reduced CD4+ T lymphocytes along with results from animal studies demonstrate the importance of T lymphocytes in protection against this fungus (2, (4) (5) (6) (7) (8) . The specific cells and mechanisms by which cryptococci are cleared from the host have not been completely elucidated. Natural killer (NK)' and T cells are two types of lymphocytes that contribute to protection against the eukaryotic microorganism C. neoformans. The ability of NK cells to kill cryptococci in vitro and in vivo has been documented in the murine model (9) (10) (11) (12) (13) (14) (15) (16) . Results from additional in vitro studies with rat and mouse NK cells provide solid evidence that NK cells interact directly with cryptococcal cells to kill the organism ( 14, 15, 17, 18) . Mouse NK cells inflict damage on these yeast-like targets by attaching to the cryptococcal cells through many microvilli ( 14, 17) . The binding interaction results in rearrangement of the cytoplasmic organelles in the NK cell followed by killing of the cryptococcal cell ( 1 1, 17) . NK cells are thought to contribute to clearance ofthe organism early after infection before the sensitized T lymphocytes have been induced (9, 12, (19) (20) (21) . Furthermore, evidence from the murine model indicates that, after the anticryptococcal cell-mediated immune response is induced, the sensitized T cells play the major role in directing the protective mechanisms against this opportunistic pathogen (4, 6-8, 22, 23) . Although it is possible that the sensitized T cells function indirectly through other effector cells to eliminate the organisms from the host, it is also possible that the T lymphocytes interact directly with the cryptococci to mediate killing. Findings from two studies support the latter concept (4, 24) . T lymphocytes from C. neoformans-immunized mice were shown to inhibit the in vitro growth of cryptococci (24) , thus indicating that immune T cells, like NK cells, may directly interact with the cryptococcal cells to eliminate the microorganism. Furthermore, in the mouse model, CD4+ T cells are necessary for the formation of multinucleate giant cells around C. neoformans cells at the site ofinfection, an event that results in containment and eventual elimination of the organism (4) .
Since target recognition patterns are different between mouse NK cells and human NK cells (25) , there has been some question as to whether human lymphocytes, like mouse lymphocytes, have the ability to bind and directly inhibit cryptococcal growth. For instance, mouse NK cells recognize and kill YAC-1 tumor target cells whereas human NK cells do not effectively kill YAC-I targets but rather lyse other targets such as K562 tumor cells (25) . The effects of human NK cells but not T lymphocytes on in vitro cryptococcal growth have been previously evaluated by Miller et al. (26) . They found that in the presence but not in the absence of anticryptococcal antibody human NK cells killed cryptococcal targets (26) . Their work establishes that, with the appropriate signal(s), human NK cells have the capacity to kill cryptococci. In contrast, there is little to no information regarding the direct interaction of freshly isolated human T cells with C. neoformans.
The purpose of the studies presented here was to determine if human NK cells and T lymphocytes would form conjugates with cryptococcal target cells and inhibit target growth in the absence of opsonizing components such as anticryptococcal antibody or complement. Our approach to assessing the anticryptococcal activity of NK cell-and T lymphocyte-enriched fractions was to avoid lymphocyte-enrichment techniques that rely on the use of antibody that could bind to and activate the lymphocytes. Typically, techniques that do not use antibody in the enrichment procedure provide cell populations highly enriched for T lymphocytes; however, they are less effective for purification of NK cells.
Results from our studies with human PBMC fractions show that monocytes, NK cells, and T lymphocytes bind to and inhibit the growth of the fungal target, C. neoformans. The (28) . It exhibits the surface phenotype   of CD3-, CD4-, CD5-, CD8-, CD16+, CD38+, CD45+, HLA-DR+, DP+, DQ+, 30, 40 , and 50% Percoll (285 mosmol/kg H20) in PBS supplemented with 10% FBS. The NK cellenriched population was collected from the interface between the 40 and 50% Percoll whereas the T cell-enriched fraction was collected from the bottom ofthe gradient. Approximately 25% ofthe cells recovered were in the low buoyant density fraction and 75% were in the high buoyant density fraction.
Complement-mediated mass cytolysis ofselected cell populations. Complement-mediated lysis was employed as a negative selection procedure for eliminating CDl 5+ monocytes, CD 16+ NK cells, or CD3+ T cells from selected cell populations. Negative selection procedures were preferred for our purposes rather than positive selection procedures because the latter have the potential to activate the effector cells (25 ) . For depletion of CD 1 5+ cells or CD 1 6+ cells, 5 X 106 effector cells were suspended in 0.5 ml of HBSS (Gibco Laboratories) containing 2 ,ug of anti-CD 15+ or anti-CD 16+ purified monoclonal antibody, respectively, and incubated for 30 min at 25°C. After incubation, the cells were washed with HBSS, resuspended in 1 ml of Low-Tox-H rabbit complement (Accurate Chem. & Sci. Corp., Westbury, NY), and incubated for 45 min at 37°C. After washing the cells with HBSS, CM + 10% FBS was added to adjust the sample to the original volume. Cell numbers were not adjusted to account for the cells that lysed, however, viability counts were performed to assess the effectiveness ofthe depletions. For depletion of CD3+ cells, the effector cells were treated as indicated above with 2 Ag of anti-CD3 antibody and washed in HBSS.
The effector cells were then resuspended in 0. washed in CM + 10% FBS and resuspended in 0.2 ml of 0.01% (vol/ vol) Triton X-100 in H20 to lyse the effector cells, a treatment previously determined to have no effects on the viability of cryptococci (20) . The resulting lysates were serially diluted in sterile physiological saline and plated in duplicate on modified Sabouraud's dextrose agar. After 3 d of incubation at room temperature, CFU were enumerated and the percentage of cryptococcal growth inhibition was determined according to the following formula: % cryptococcal growth inhibition = [(mean control CFU -mean experimental CFU)/mean control CFU] x 100.
C. neoformans growth inhibition assay with lymphocyte-enriched effector cells. To assess inhibition of C. neoformans growth by lymphocytes, a modification of the assay previously described by Murphy and McDaniel ( 13) was used. Preliminary studies were done to determine the effector cell/target cell (E/T) ratio and the culture conditions that would consistently result in measurable levels of cryptococcal growth inhibition. We found that an E/T ratio of 2:1 consistently gave anticryptococcal activity when human lymphocytes were the effector cells. On the basis ofresults from our preliminary experiments, the following procedure was used for the experiments presented in this paper. Briefly, 106 effector cells (NWN lymphocytes, low density lymphocytes, or high density lymphocytes) and 5 X 105 cryptococcal target cells suspended in CM + 10% FBS were added to quadruplicate wells of a flat-bottom 96-well microtiter plate (Linbro Scientific Co., Hamden, CT). Quadruplicate control wells contained 5 x I05 cryptococcal target cells in CM + 10% FBS. Both experimental and control well volumes were adjusted to 0.25 ml with CM + 10% FBS. After incubating the plate for 18 h at 370C in 7% CO2, the content of each well was serially diluted in sterile physiological saline and plated in duplicate on modified Sabouraud's dextrose agar plates. After 3 d of incubation at room temperature, CFU were enumerated and the percentage of cryptococcal growth inhibition was determined according to the formula given above.
Assay for effector cell-target cell conjugate formation. Binding of effector cells to C. neoformans target cells was assessed according to the procedure previously described ( 10, 14, 17) . Briefly, effector cells were mixed with cryptococcal target cells at an E/T ratio of 2:1 in CM + 10% FBS. The effector cells were incubated with cryptococcal cells for 18 h at 370C in 7% C02, conditions initially determined to give maximum human effector cell-cryptococci binding. To facilitate counting of the effector cell-cryptococcal cell conjugates, the samples were stained with 0.25% alcian blue in serum-free RPMI 1640 medium. Duplicate samples of each conjugate suspension were counted by light microscopy, and the percentage ofeffector cells bound to target cells was calculated by counting a minimum of 200 effector cells.
Cell preparation for electron microscopy. Monocyte effector cells were mixed with cryptococci at an E/T ratio of 100:1 in 0. with HBSS, resuspended in 0.2 ml of serum-free RPMI 1640 medium, and placed on Kodacel film that had been precoated with 0.1% (wt/ vol) poly-L-lysine in carbonate buffer. The cell suspensions were incubated on the film for 1 h at 4VC to allow the cells to adhere to the film.
The samples were then fixed, prepared for scanning electron microscopy or transmission electron microscopy, and viewed as previously described ( 17) . For immunoelectron microscopy, the T lymphocyte-enriched effector cells were mixed with C. neoformans cells and incubated as described above. After the 18 h incubation, the cell mixtures were washed with ice-cold PBS containing 0.1% sodium azide (pH 7.2). The antibody or UPC10 (20 ,ug protein/ml) for 30 min at room temperature. The cells were washed twice before they were treated for 30 min with 100 Ml of monodispersed carboxylate latex beads conjugated to goat anti-mouse IgG diluted so that the final suspension contained 100 beads per effector cell. The unbound beads were removed by washing and then the cells were resuspended in cacodylate buffer containing 0.1 M sucrose and 1% glutaraldehyde before being put onto poly-L-lysinecoated Kodacel film. After adhering the cells to the Kodacel film, the samples were treated as described previously ( 17) .
Statistical analysis. Means and SEM were calculated and Student's t test was used to analyze the data. Groups were considered to be significantly different when the P value was < 0.05. Where indicated, linearregression analysis and correlation coefficients were determined.
Results
Characterization of PBMC subsets. Human PBMC were initially separated into plastic adherent and nonadherent cells. The nonadherent cells were further fractionated on nylon wool, and the NWN cells were centrifuged on Percoll density gradients. Before assessing the anticryptococcal activity of the various PBMC fractions, experiments were performed to characterize the predominant cell type(s) present in each fraction. The plastic adherent fractions ofthe PBMC were examined by flow cytometric analysis and found to contain > 92% CD15+ cells, a phenotype characteristic ofmonocytes. Thus, for convenience hereafter the plastic-adherent fractions ofPBMC will be referred to as monocytes. The NWN fractions, the low buoyant density lymphocytes (large granular lymphocyte [ LGL] or NK cell-enriched fraction), and the high buoyant density lymphocytes (T cell-enriched fraction) were (a) phenotyped using flow cytometric analyses, (b) evaluated for enrichment of NK cell activity with the K562 cytolytic assay, and (c) assessed for binding and inhibition ofC. neoformans target cells. Flow cytometric analyses demonstrated that the NWN cells were predominantly CD3+ cells with a small percentage ofCD 15+ cells and moderate but equivalent percentages of CD56+ and CD16+ cells (Table I) . Similar phenotypic analyses after Percoll gradient fractionation of the NWN cells demonstrated enrichment of CD 16+ and CD56+ cells, a phenotype typical of NK cells, in the LGL-containing low density lymphocyte fraction whereas the high density fraction contained > 92% CD3+ cells typical ofT lymphocytes (Table I) . NWN cells displayed moderate levels of NK cell activity (Table I) and, as expected, enrichment of CD16+ and CD56+ cells in the LGL fraction correlated with the enrichment of NK cell activity against K562 target cells. In contrast, enrichment of CD3+ lymphocytes in the T cell-enriched fraction correlated with a depletion of NK cell activity against K562 target cells (Table I ). The levels of C. neoformans binding and growth inhibition were comparable when each of these three PBMC fractions were used as the source of effector cells (Table I) (Fig. 1  A) . The monocytes exhibited broadly ruffled or folded membranes that often surrounded either completely or partially the cryptococcal cells (Fig. 1 A) . The transmission electron micrographs of the same samples demonstrated phagocytosed cryptococci within the monocytes (Fig. 1 B) . In contrast to the monocytes, the lymphocytes were smaller and had a more rounded shape. The membranes of many ofthe cells in the NK cell-enriched fraction appeared very rough due to their surfaces being covered with numerous thin microvilli. Many of the effector cell-C. neoformans conjugates observed within the NK cell-enriched population had effector cells that made contact with the capsular surface of the cryptococcal cell through the tips or edges of several microvilli of the effector cell (Fig. 1  C) . Occasionally, in these preparations, conjugates were found in which the effector cells resembled the effector cells in the T cell-enriched fractions (Fig. 1, E and F) . Stereo-paired scanning electron micrographs (not shown) and transmission electron micrographs of cryptococci bound to effector cells in the NK cell-enriched population (Fig. 1 D) showed that the microvilli ofthe effector cells penetrated the cryptococcal capsule. In contrast, the majority of the cells in the T cell-enriched fraction displayed wavy folded surfaces. The cell-cell contact sites in the conjugates in the T cell-enriched population were formed by wide folded protrusions of the lymphocyte membrane extending to the surface ofthe cryptococcal cell ( Fig. 1 E  and F) . The actual area of contact between the lymphocyte and the cryptococcal cell was much greater than was observed with many ofthe effector cells ofthe NK cell-enriched populations that were bound to cryptococci by numerous microvilli ( Fig. 1 C and D) . Scanning electron microscopy was used for viewing C. neoformans-effector cell interactions with NK and T cell-enriched fractions from six different individuals, and cell-cell interactions similar to those shown in Fig. 1 for the respective cell fractions were observed in all cases. Inhibition ofC. neoformans growth byfractions ofhuman PBMC. To compare human PBMC fractions with regard to anticryptococcal activity and NK cell activity, monocytes, NWN cells, and NK and T cell-enriched fractions were used as effector cells in parallel cryptococcal growth inhibition and K562 cytolytic assays. Anticryptococcal activity mediated by monocytes varied significantly depending upon the ratio of monocytes to cryptococci used in the growth inhibition assay (Table II) . Optimal levels of monocyte-mediated cryptococcal growth inhibition occurred with an E/T ratio of 100:1. At a monocyte/cryptococci ratio of 2:1, cryptococcal growth was not inhibited, but rather significantly enhanced in relation to the C. neoformans control samples (P = 0.004) (Table II) . The increased cryptococcal growth may have been due to the greater numbers of C. neoformans cells per monocyte at this E/T ratio. Possibly the larger numbers of cryptococci destroyed the monocytes, thereby releasing monocyte cytoplasmic components that enhanced the growth of the cryptococci. The viability of the monocytes at the end of the assay in wells with 2:1 E/T ratios was not determined. As expected, monocytes exhibited moderate levels of anti-K562 activity in the 18-h 5"Cr release assay at an E/T ratio of 50:1 (Table II) .
Anticryptococcal activities at four different E /T ratios with LGL and T cell fractions of PBMC from a typical sample are shown in Fig. 2 . In several cases, the anticryptococcal activity of LGL fractions was also assessed at a 100:1 E/T ratio. At this high E/T ratio, there was considerable variation in detection of anticryptococcal activity among individuals. On occasion, we observed greatly reduced growth inhibition with the LGL fractions at an E/T ratio of 100:1. Because demonstration ofLGLmediated cryptococcal growth inhibition was not consistently observed at an E/T ratio of 100:1 but was consistently demonstrated at an E/T ratio of 2:1 and because monocytes did not inhibit the growth of C. neoformans at a 2:1 ratio, we used a 2:1 E/T ratio with lymphocyte populations as effector cells throughout the remainder of the study.
After rigorous monocyte depletion by adherence to plastic and nylon wool, parallel anticryptococcal and anti-K562 activities of lymphocytes from 10 different donors were assessed at an E/T ratio of 2:1 (Fig. 3) . In some cases, data from cells of the same donor are -included in Table I and Fig. 3 , however, because sufficient numbers of cells to perform all of the assays were not obtained from each donor, results from some individuals are included in Table I that are not represented in Fig. 3 and vice versa. Wide ranges ofboth cryptococcal growth inhibition and K562 cytolysis were observed depending on the donor (4-33% cryptococcal growth inhibition and 15-66% 5"Cr release from K562) when NWN cells were used as the effector cells (Fig. 3, a) . However, linear-regression analysis demonstrated a positive correlation between the level of cryptococcal growth inhibition and the level of K562 cytolytic activity of NWN cells (r = 0.68), suggesting that the NK cells that mediate K562 cytolysis might be responsible for the inhibition of cryptococcal growth. Similar correlation analyses were done with NK cell activity data and cryptococcal growth inhibition data obtained with the NK cell-enriched, LGL fractions (Fig.  3, b) as effector cells and with the NK cell-depleted (T cellenriched) fractions (Fig. 3, c) as effector cells. The NK cellenriched LGL fractions exhibited a range of 8-52% K562 cytolytic activity whereas the cryptococcal growth inhibitory activity ranged from 4 to 56% with a positive correlation between the two parameters of r = 0.9 (Fig. 3, b) . In contrast, the T cell-enriched fractions displayed significantly lower levels of K562 cytolytic activity (1-23%; P < 0.001) as would be expected with depletion ofNK (CD56+ and CD16+) cells. However, the T cell-enriched fractions had levels of anticryptococcal activity similar to that ofthe NK cell-enriched populations (2-47%) (Fig. 3, c) . When the T cell-enriched fractions were used as the source of effector cells, the correlation between K562 cytolytic activity and cryptococcal growth inhibition was lower than when NK cell-enriched fractions were the effector cells (r = 0.48 vs. r = 0.9). These data suggest that both the NK and the T cell-enriched populations contained effector cell(s) capable of limiting cryptococcal growth. measuring their anticryptococcal activity using an E/T ratio of 100:1 in an 18-h assay. Anti-CD 15 (IgM) antibody and C treatment reduced the anticryptococcal activity of the monocyte fraction when compared with the control groups that were treated with C alone or anti-CD16+ (IgM) antibody and C (Fig. 4) .
To confirm that the anti-K562 activities and the anticryptococcal activities displayed by the LGL (NK cell-enriched) fractions and the T cell-enriched fractions were not due to contaminating monocytes, each effector cell fraction was treated with C alone, anti-CD 15 and C, or anti-CD 1 6 and C before determining the levels of activity against K562 or cryptococcal targets. Removal of the CD15+ monocytes from the LGL or the T cell-enriched fraction did not reduce the anti-K562 activity nor the anticryptococcal activity of either the LGL or the T cell-enriched fraction when compared with the respective activities of the PBS + C-treated controls (Fig. 5) . In contrast, anti-CD 16 and C treatment ofthe LGL (NK cellenriched) fraction significantly reduced both the anti-K562 activity (P < 0.001) and the anticryptococcal activity (P = 0.001) in comparison to the respective activities of the control cell fractions (Fig. 5) . Anti-CD16 and C treatment of the T cellenriched fraction significantly diminished the anti-K562 activity (P = 0.001) of that fraction, however, the same treatment did not reduce the anticryptococcal activity of the T cellenriched fraction (Fig. 5) .
Since the anti-CD 16 and C treatment significantly reduced but did not completely abrogate the NK cell activity (P < 0.001) nor the anticryptococcal activity (P = 0.001) of the LGL (NK cell-enriched) fraction and did not reduce the anticryptococcal activity of the T cell-enriched fraction, conclusions were difficult to make, so we extended the mass cytolysis studies. The next series of PBMC samples were separated as before into LGL and T cell-enriched fractions before treating the cells with mouse IgM as an isotype control for the anti-CD16 or with anti-CD 1 6 followed by C treatment. Samples from each cell fraction were retained as untreated controls. The various treated fractions were then (a) analyzed by flow cytometry to determine the number ofCD16+ and CD3+ cells in the samples, (b) assessed for their ability to lyse K562 cells, and (c) evaluated for their anticryptococcal activity.
The flow cytometric data demonstrated that the LGL fraction was enriched for CD 16+ cells as compared with the T cell fraction (Fig. 6, A vs. D, untreated groups) . The data also confirmed that there was considerable contamination of the LGL fraction with CD3+ cells (Fig. 6 A, untreated group) . In contrast, the T cell-enriched fraction contained a very minimal number of CD16+ cells (Fig. 6 D, untreated group) . The cytometric data also showed that the anti-CD 16 antibody and C treatment depleted CD16+ cells from both the LGL and the T cell-enriched fractions without significantly altering the number of CD3+ cells in either cell fraction (Fig. 6 A for LGL and D for T cells). The anti-CD 16 and C treatment of the LGL fractions (Fig.  6 B) and the T cell-enriched fraction (Fig. 6 E) significantly reduced the NK cell activity as measured by the lysis of K562 cells of the LGL fraction but not the T cell fraction (LGL, P < 0.023; T cell, P = 0.33). Although the anticryptococcal activity of the LGL fractions after treatment with anti-CD 16 + C was always slightly lower than the anticryptococcal activity of the IgM + C-treated control population, the difference was never significant (Fig. 6 C) . Furthermore, anti-CD16 and C treatment of the T cell-enriched fraction did not significantly affect the anticryptococcal activity (Fig. 6 F) . Because the anti-CD 16 and C treatment reduced the NK cell activity but did not significantly affect the anticryptococcal activity, it appeared that the CD3+ T cells were inhibiting the cryptococcal growth. Our electron microscopic observations of cells in the T cellenriched fraction binding to C. neoformans and our findings that the binding characteristics differed from those ofother cell populations (Fig. 1 ) are in agreement with this suggestion that human T cells might directly affect cryptococci.
To further address the possibility that human T cells directly inhibit cryptococcal growth, a study similar to the previous one was done, but the cell fractions were treated with anti-CD3 antibody and C or an appropriate isotype-matched control antibody (UPC 10) and C rather than anti-CD 16 before determining the anticryptococcal activities ofthe cell fractions. The efficacy of the depletion was monitored by flow cytometry. The anti-CD3 and C treatment greatly reduced as compared with the UPC1O + C controls the number of CD3+ cells in the LGL and the T cell-enriched fractions without affecting the numbers of CD 16+ cells (Fig. 7, A and D, respectively) . Moreover, the anti-CD3 and C treatment did not affect the NK cell activity ofeither cell fraction (Fig. 7, B and E) . The treatment with anti-CD3 and C, when compared with treatment with UPC 10 and C, had no effect on the anticryptococcal activity of the LGL fraction (Fig. 7 C) but did significantly diminish the anticryptococcal activity of the T cell-enriched fraction (P < 0.002; Fig. 7 F) .
Effect ofthe human NK cell clone NK3.3 on C. neoformans growth. The reduction of T cells in the LGL population by anti-CD3 antibody and C treatment did not result in a concomitant reduction in anticryptococcal activity (Fig. 7 C) . This result suggested that the NK cells in the population were responsible for the remaining cryptococcal growth inhibitory activity.
Since there was a small number of CD3+ T cells in the anti-CD3 and C-treated LGL population, we could not be certain the anticryptococcal activity was imparted by NK cells. To determine if human NK cells in the absence of opsonins and T cells could inhibit the growth of C. neoformans, we assessed the ability of the human NK cell clone NK 3.3 to inhibit the growth of C. neoformans. Data presented in Fig. 8 show that as the NK 3.3 cell/cryptococcal cell ratios were increased from 1:1 to 8: 1, the inhibition of C. neoformans growth increased from 0 to 73% (Fig. 8 A) . With similar E/T ratios, the percent 5"Cr release from K562 tumor targets ranged from 10 to 60% (Fig. 8 B) , demonstrating the level of NK cell activity of this clone.
Immunoelectron microscopy. To confirm that T lymphocytes were the effector cells attached to C. neoformans, immunolabeling with mouse IgGu monoclonal anti-CD3 antibody or an irrelevant IgG2,, UPC10, followed by anti-mouse IgG bound to latex beads was performed. When conjugates in the T lymphocyte-C. neoformans mixtures were immunolabeled with anti-CD3 and the secondary antibody and viewed on the scanning electron microscope, we found that the effector cells attached to cryptococci had numerous latex spheres associated with their surfaces (Fig. 9 A) whereas, in the samples treated with the irrelevant isotype control antibody and secondary reagent, the lymphocytes attached to cryptococci did not have latex spheres associated with them (Fig. 9 B) . These results demonstrate that the immunolabeling was specific for T lymphocytes and that the effector cells attached to cryptococci were indeed CD3+, a characteristic of T cells.
Discussion
The anticryptococcal activities of human PBMC have been studied by several laboratories, however, there remains some question as to whether lymphocyte subsets are capable of attaching to and inhibiting the growth of cryptococci (26, (33) (34) (35) (36) (37) (38) (39) . Freshly isolated PBMC populations contain four major subsets of cells, B lymphocytes, monocytes, T lymphocytes, and NK cells. The latter three populations of cells have been ties of the LGL and T cell fractions. Thus, we concluded that the cells having a monocyte phenotype were not responsible for the anticryptococcal activity of the LGL or T cell fractions of human PBMC. This conclusion is supported by two additional observations. First, the monocyte interactions with cryptococci as shown by electron microscopy were different than the interactions of the plastic nonadherent populations with C. neoformans, in that the monocytes bound and phagocytized the organism (Fig. 1, A and B) , whereas the cells in the lymphocyte fractions bound to the cryptococci without phagocytizing the organism (Fig. 1, C-F) . Secondly, we observed, as have others (40) , that the monocyte-mediated anticryptococcal activity diminished as the E/T ratios were reduced from 100:1 to 1:1. In fact, with monocytes as effector cells at a 2:1 E/T ratio, which was the E/T ratio used in the anticryptococcal assays with LGL or T lymphocytes as effector cells, no anticryptococcal activity was detected (Table II) . Considered together, our data eliminate the possibility that contaminating monocytes were responsible for the anticryptococcal activity detected with the LGL and T cell-enriched fractions.
In the experiments in which anti-CD 15 and C were used to eliminate monocytes or anti-CD16 and C were used to eliminate NK cells from the LGL or the T cell-enriched fractions, we noted that the anti-CD 1 6 and C treatment did indeed significantly reduce the NK cell activity as measured by 51Cr release from tumor target cells and the anticryptococcal activity of the LGL fraction, however, the treatment did not alter the anticryptococcal activity of the T cell fraction. These data, like our initial data from studies with NWN cell fractions, indicated that both NK and T lymphocytes were active against cryptococci.
Because we had not phenotyped the effector cells after mass cytolysis in our initial experiments with LGL and T cell fractions (Fig. 5) , we repeated the studies with effector cells from three to four additional subjects. With these cell populations, the number of cells having a CD 16+ or a CD3+ phenotype, the anti-K562 activity, and the anticryptococcal activity were determined for both the untreated cell populations and the antibody and C-treated effector cell populations. Again, anticryptococcal activity was noted with both the LGL-enriched fraction and T cell-enriched fraction (Figs. 6 and 7) . Although the anti-CD 16 and C treatment greatly reduced the number of CD16+ cells in the LGL fraction and reduced the NK cell activity as determined by anti-K562 activity, there was only a minimal reduction in the anticryptococcal activity with the LGL fractions. This latter finding could be explained by the T cells remaining in the anti-CD 16 and C-treated samples being responsible for the anticryptococcal activity. These data were corroborated by the data obtained from the T cell-enriched ( Fig. 1) antibody (Fig. 9 ). Our data, from studies in which we showed a strong correlation between anti-K562 activity and anticryptococcal activity with the LGL fraction of effector cells and from our depletion studies with anti-CD 16 and C, strongly suggest that human NK cells can limit the growth ofcryptococci in the absence ofcomplement or anticryptococcal antibodies. This concept is also supported by the observation that the anti-CD3 and C treatment of the LGL fraction greatly reduced the numbers of T cells without significantly affecting the NK cell or the anticryptococcal activities. Our conclusion that human NK cells can inhibit the growth ofC. neoformans differs from the conclusion of Miller et al. (26) who observed that human NK cells killed cryptococci only in the presence of anticryptococcal antibody. We found as did Miller et al. (26) that performing the anticryptococcal assays with an E:T ratio of 100:1 with human LGL as the effector cells did not consistently result in inhibition of cryptococcal growth. However, by using an E/T ratio of 2:1 as we have routinely done for effector cell-C. neoformans conjugate assays with murine NK cells ( 17), we were able to detect anticryptococcal activity of human LGL as well as ofhuman T cells.
With the human NK cell clone NK 3.3 as effector cells, we confirmed that human NK cells can inhibit cryptococcal growth in the absence of opsonizing agents. The NK 3.3 cell line inhibited the growth of C. neoformans under the same conditions as were used for the freshly isolated human NK cells. The percent inhibition of C. neoformans growth increased as the E/T ratio of NK 3.3 cells to cryptococci was increased from 1:1 to 8:1, and the increase in anticryptococcal activity paralleled the increase in NK cell activity observed with increasing E/T ratios and K562 tumor cells as targets. Since NK 3.3 cells are equivalent to IL-2-activated NK cells (28) , it may be that the anticryptococcal activity detected with freshly isolated human LGL was mediated by a population of activated NK cells present in the peripheral blood. Further studies are necessary to address this.
Scanning and transmission electron microscopy ofthe conjugates formed with the LGL-enriched and the T cell-enriched fractions revealed two different types of binding interactions. Many of the LGL effector cells attached to the cryptococci through numerous microvilli whereas almost all of the T lymphocyte effector cells attached to the cryptococcal cells by a large area of membrane adhering like a suction cup to the surface of the cryptococcal cell. Furthermore, all the effector cells bound to cryptococci that labeled with the anti-CD3 and antibody conjugated to latex beads had the physical attachment characteristics described for the T cell fraction. These observations suggest that human NK 
